Biotechnology
Compare Stocks
2 / 10Stock Comparison
QSI vs CDNA
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
QSI vs CDNA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $193M | $1.11B |
| Revenue (TTM) | $2M | $413M |
| Net Income (TTM) | $-104M | $-8M |
| Gross Margin | -200.5% | 48.2% |
| Operating Margin | -62.1% | -3.3% |
| Forward P/E | — | 22.8x |
| Total Debt | $4M | $20M |
| Cash & Equiv. | $22M | $65M |
QSI vs CDNA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 20 | May 26 | Return |
|---|---|---|---|
| Quantum-Si incorpor… (QSI) | 100 | 9.9 | -90.1% |
| CareDx, Inc (CDNA) | 100 | 37.5 | -62.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: QSI vs CDNA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
QSI is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 3.79, Low D/E 1.9%, current ratio 7.64x
CDNA carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.39
- Rev growth 13.8%, EPS growth -143.0%, 3Y rev CAGR 5.7%
- 385.1% 10Y total return vs QSI's -90.1%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 13.8% revenue growth vs QSI's -20.3% | |
| Quality / Margins | -2.0% margin vs QSI's -56.1% | |
| Stability / Safety | Beta 1.39 vs QSI's 3.79 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +45.2% vs QSI's -18.3% | |
| Efficiency (ROA) | -1.9% ROA vs QSI's -42.7%, ROIC -5.7% vs -38.1% |
QSI vs CDNA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
QSI vs CDNA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
CDNA leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CDNA is the larger business by revenue, generating $413M annually — 222.9x QSI's $2M. CDNA is the more profitable business, keeping -2.0% of every revenue dollar as net income compared to QSI's -56.1%. On growth, CDNA holds the edge at +39.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $2M | $413M |
| EBITDAEarnings before interest/tax | -$112M | $2M |
| Net IncomeAfter-tax profit | -$104M | -$8M |
| Free Cash FlowCash after capex | -$96M | $65M |
| Gross MarginGross profit ÷ Revenue | -2.0% | +48.2% |
| Operating MarginEBIT ÷ Revenue | -62.1% | -3.3% |
| Net MarginNet income ÷ Revenue | -56.1% | -2.0% |
| FCF MarginFCF ÷ Revenue | -51.7% | +15.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -69.4% | +39.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +9.1% | +126.3% |
Valuation Metrics
CDNA leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $193M | $1.1B |
| Enterprise ValueMkt cap + debt − cash | $175M | $1.1B |
| Trailing P/EPrice ÷ TTM EPS | -1.92x | -53.60x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 22.85x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 79.07x | 2.92x |
| Price / BookPrice ÷ Book value/share | 0.88x | 3.77x |
| Price / FCFMarket cap ÷ FCF | — | 30.66x |
Profitability & Efficiency
CDNA leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
CDNA delivers a -2.6% return on equity — every $100 of shareholder capital generates $-3 in annual profit, vs $-47 for QSI. QSI carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to CDNA's 0.06x. On the Piotroski fundamental quality scale (0–9), CDNA scores 5/9 vs QSI's 2/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -47.3% | -2.6% |
| ROA (TTM)Return on assets | -42.7% | -1.9% |
| ROICReturn on invested capital | -38.1% | -5.7% |
| ROCEReturn on capital employed | -42.9% | -5.8% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 |
| Debt / EquityFinancial leverage | 0.02x | 0.06x |
| Net DebtTotal debt minus cash | -$17M | -$46M |
| Cash & Equiv.Liquid assets | $22M | $65M |
| Total DebtShort + long-term debt | $4M | $20M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (Dividends Reinvested)
CDNA leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CDNA five years ago would be worth $2,759 today (with dividends reinvested), compared to $943 for QSI. Over the past 12 months, CDNA leads with a +45.2% total return vs QSI's -18.3%. The 3-year compound annual growth rate (CAGR) favors CDNA at 37.7% vs QSI's -12.0% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -15.5% | +12.0% |
| 1-Year ReturnPast 12 months | -18.3% | +45.2% |
| 3-Year ReturnCumulative with dividends | -31.9% | +161.1% |
| 5-Year ReturnCumulative with dividends | -90.6% | -72.4% |
| 10-Year ReturnCumulative with dividends | -90.1% | +385.1% |
| CAGR (3Y)Annualised 3-year return | -12.0% | +37.7% |
Risk & Volatility
CDNA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CDNA is the less volatile stock with a 1.39 beta — it tends to amplify market swings less than QSI's 3.79 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CDNA currently trades 92.3% from its 52-week high vs QSI's 31.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.79x | 1.39x |
| 52-Week HighHighest price in past year | $3.10 | $23.24 |
| 52-Week LowLowest price in past year | $0.69 | $10.96 |
| % of 52W HighCurrent price vs 52-week peak | +31.6% | +92.3% |
| RSI (14)Momentum oscillator 0–100 | 58.9 | 56.4 |
| Avg Volume (50D)Average daily shares traded | 4.4M | 667K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates QSI as "Buy" and CDNA as "Buy". Consensus price targets imply 11.9% upside for CDNA (target: $24) vs 2.0% for QSI (target: $1).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $1.00 | $24.00 |
| # AnalystsCovering analysts | 2 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +7.9% |
CDNA leads in 5 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics.
QSI vs CDNA: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is QSI or CDNA a better buy right now?
For growth investors, CareDx, Inc (CDNA) is the stronger pick with 13.
8% revenue growth year-over-year, versus -20. 3% for Quantum-Si incorporated (QSI). Analysts rate Quantum-Si incorporated (QSI) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — QSI or CDNA?
Over the past 5 years, CareDx, Inc (CDNA) delivered a total return of -72.
4%, compared to -90. 6% for Quantum-Si incorporated (QSI). Over 10 years, the gap is even starker: CDNA returned +385. 1% versus QSI's -90. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — QSI or CDNA?
By beta (market sensitivity over 5 years), CareDx, Inc (CDNA) is the lower-risk stock at 1.
39β versus Quantum-Si incorporated's 3. 79β — meaning QSI is approximately 172% more volatile than CDNA relative to the S&P 500. On balance sheet safety, Quantum-Si incorporated (QSI) carries a lower debt/equity ratio of 2% versus 6% for CareDx, Inc — giving it more financial flexibility in a downturn.
04Which is growing faster — QSI or CDNA?
By revenue growth (latest reported year), CareDx, Inc (CDNA) is pulling ahead at 13.
8% versus -20. 3% for Quantum-Si incorporated (QSI). On earnings-per-share growth, the picture is similar: Quantum-Si incorporated grew EPS 28. 2% year-over-year, compared to -143. 0% for CareDx, Inc. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — QSI or CDNA?
CareDx, Inc (CDNA) is the more profitable company, earning -5.
6% net margin versus -41. 6% for Quantum-Si incorporated — meaning it keeps -5. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CDNA leads at -5. 5% versus -39. 8% for QSI. At the gross margin level — before operating expenses — CDNA leads at 67. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is QSI or CDNA more undervalued right now?
Analyst consensus price targets imply the most upside for CDNA: 11.
9% to $24. 00.
07Which pays a better dividend — QSI or CDNA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is QSI or CDNA better for a retirement portfolio?
For long-horizon retirement investors, CareDx, Inc (CDNA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+385.
1% 10Y return). Quantum-Si incorporated (QSI) carries a higher beta of 3. 79 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CDNA: +385. 1%, QSI: -90. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between QSI and CDNA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.